Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant.
CTL
T‐cell
adoptive immunotherapy
allogeneic stem cell transplantation
haemopoietic stem cell transplant
opportunistic infection
systemic fungal infection
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
09
2020
revised:
18
12
2020
revised:
12
01
2021
accepted:
12
01
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
Adoptive immunotherapy using donor-derived antigen-specific T-cells can prevent and treat infection after allogeneic haemopoietic stem cell transplant (HSCT). We treated 11 patients with a prophylactic infusion of 2 × 10 T-cell products were successfully generated in all patients with 10 products responsive to 6 or 7 infections. T-cell infusions were associated with increases in antigen-experienced activated CD8 Rapid reconstitution of immunity to a broad range of viral and fungal infections can be achieved using a multi-pathogen-specific T-cell product. The development of GVHD after T-cell infusion suggests that infection-specific T-cell therapy after allogeneic stem cell transplant should be combined with other strategies to reduce graft-versus-host disease.
Identifiants
pubmed: 33747509
doi: 10.1002/cti2.1249
pii: CTI21249
pmc: PMC7960021
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1249Informations de copyright
© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biol Blood Marrow Transplant. 2020 Feb;26(2):323-332
pubmed: 31618690
Blood. 2017 Apr 20;129(16):2316-2325
pubmed: 28209721
Immunol Cell Biol. 2018 Jul;96(6):553-561
pubmed: 29726044
Blood. 2013 Jan 3;121(1):207-18
pubmed: 23152545
Transplantation. 2011 Nov 27;92(10):1077-84
pubmed: 22002347
J Clin Invest. 2015 Jul 1;125(7):2677-89
pubmed: 26053664
Nat Med. 2006 Oct;12(10):1160-6
pubmed: 16998485
Sci Transl Med. 2014 Jun 25;6(242):242ra83
pubmed: 24964991
Bone Marrow Transplant. 2009 Jan;43(1):13-9
pubmed: 18762764
Clin Transl Immunology. 2015 Aug 14;4(8):e40
pubmed: 26366286
Cancer. 2004 May 1;100(9):1892-901
pubmed: 15112270
Intern Med J. 2013 Feb;43(2):191-6
pubmed: 22646924
Nat Med. 1996 May;2(5):551-5
pubmed: 8616714
Blood. 2013 May 2;121(18):3745-58
pubmed: 23435462
Blood. 2008 Apr 15;111(8):4392-402
pubmed: 17878399
Ann N Y Acad Sci. 2005 Dec;1062:104-15
pubmed: 16461793
Lancet. 2003 Oct 25;362(9393):1375-7
pubmed: 14585640
Biol Blood Marrow Transplant. 2015 Sep;21(9):1641-5
pubmed: 26079442
Biol Blood Marrow Transplant. 2013 May;19(5):725-34
pubmed: 23380344
Cytotherapy. 2013 Mar;15(3):344-51
pubmed: 23579059
Ann N Y Acad Sci. 1991 Dec 30;636:184-95
pubmed: 1665321
Blood. 2010 Nov 18;116(20):4360-7
pubmed: 20625005
Biol Blood Marrow Transplant. 2007 Jun;13(6):707-14
pubmed: 17531781
Blood. 2005 Dec 15;106(13):4397-406
pubmed: 16123217
Blood. 2002 Jun 1;99(11):3916-22
pubmed: 12010789
Cancer Res. 2001 Feb 15;61(4):1659-65
pubmed: 11245480
Exp Hematol. 2004 Mar;32(3):282-9
pubmed: 15003314
Clin Transl Immunology. 2020 Jul 02;9(7):e1149
pubmed: 32642063
Cytotherapy. 2015 Oct;17(10):1406-20
pubmed: 26349000
Cytotherapy. 2016 Jan;18(1):65-79
pubmed: 26552765
Cytotherapy. 2012 Oct;14(9):1119-30
pubmed: 22866666
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Mol Ther. 2013 Nov;21(11):2113-21
pubmed: 23783429
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Cytotherapy. 2012 Jul;14(6):724-32
pubmed: 22404084
Cytotherapy. 2012 Feb;14(2):182-93
pubmed: 21954837